# Original User Request

## Initial Request — 2026-10-16T14:13:46Z

The Data Agent Kit plugin needs to be configured.
Do this right away as critical functionality will either be missing or not work correctly if the plugin is not configured.
The following is a <SYSTEM_MESSAGE> not actually sent by the user. It is provided by the system as important information to pay attention to.

<SYSTEM_MESSAGE>
[Message] timestamp=2026-10-16T14:12:40Z sender=78c0bf5a-1c77-4a2a-8652-148476354625 priority=MESSAGE_PRIORITY_HIGH content=Comprehensive computational structural bioinformatics study of the human telomerase TERT–TPP1 recruitment interface versus catalytic machinery across experimental structures (7TRE, 7TRD, 7TRF, 7TRC, and 2I46) to quantify interface geometry, test computational robustness, and establish an evidence matrix evaluating the cancer vs. healthy-aging therapeutic trade-off in an accelerated single-run pipeline.

Working directory: C:\Users\hp\.gemini\antigravity\scratch\telomerase-research  
Integrity mode: development  

## Requirements

### R1. Data Acquisition & Baseline Validation
Download official mmCIF files and validation reports for the defined comparative structural dataset:
- `7TRE`: Primary TERT–TPP1 catalytic core complex (3.5 Å cryo-EM).
- `7TRD`: Related human telomerase catalytic-core reference (3.3 Å).
- `7TRF`: Telomerase catalytic core RNP with H2A–H2B.
- `7TRC`: Human telomerase H/ACA RNP lobe.
- `2I46`: Unbound TPP1 OB-fold reference structure.

Verify SHA-256 checksums, compile an immutable `data_manifest.csv` with experimental methods, resolutions, chain entity mappings, and record unresolved/missing residues and local cryo-EM coordinate uncertainty.

### R2. Sequence-Aware Chain & Residue Correspondence Mapping
Implement automated mmCIF parsers using standard structural libraries (Biopython / Gemmi) to establish sequence-based residue correspondences between homologous chains before any geometric alignment. Do not rely on nominal author residue numbers across different PDB entries.

### R3. Quantitative Interface Geometry & Interaction Profiling
For the baseline 7TRE TERT–TPP1 interface, compute:
- Exact residue–residue contact networks at defined distance cutoffs (3.5 Å, 4.0 Å, 4.5 Å).
- Buried solvent-accessible surface area ($\mathrm{BSA} = (\mathrm{SASA}_A + \mathrm{SASA}_B - \mathrm{SASA}_{AB}) / 2$).
- Polar interaction networks (hydrogen bonds and salt bridges).
- Hydrophobic packing and electrostatic surface potential.
- Local shape complementarity across the TEN–TRAP–TPP1 interface.

### R4. Cross-State Comparative Structural Analysis & Robustness Testing
Align homologous regions across 7TRD, 7TRE, and 7TRF to measure:
- Global and domain-specific Cα RMSD.
- Structural rearrangements in the TEN–TRAP domain induced by TPP1 binding.
- Sensitivity of contact networks and buried surface area to alternative distance thresholds and atom-selection conventions.
- Distinguish genuine biological conformational adjustments from differences in experimental constructs or local cryo-EM map resolution.

### R5. Evidence Matrix & Publication-Grade Synthesis Report
Generate an evidence-first markdown research report (`report.md`) accompanied by reproducible tables (`results/tables/`) and labeled figures (`results/figures/`):
- Clearly separate **Axis A (Molecular Mechanism)** from **Axis B (Therapeutic Selectivity)**.
- Document explicit limitations of static cryo-EM models and the evidence required to validate cancer-selective disruption versus stem-cell preservation.

## Acceptance Criteria

### Baseline & Data Integrity
- [ ] `data_manifest.csv` exists with verified SHA-256 hashes, source URLs, resolutions, and chain mappings for all 5 structures.
- [ ] Raw mmCIF files are stored in `data/raw/` and remain immutable.
- [ ] Script `src/telotrade/validate.py` executes cleanly without unhandled exceptions on missing residues or alternate locations.

### Quantitative Interface Analysis
- [ ] Interface contact tables generated for 7TRE at 3.5 Å, 4.0 Å, and 4.5 Å cutoffs with documented atom selections.
- [ ] Buried surface area (BSA) computed and recorded with explicit formula conventions.
- [ ] TPP1 TEL-patch residues (`Glu168–171`, `Leu183`, `Leu212`) and their corresponding TERT receptor cradle contacts quantitatively mapped.

### Cross-Structure Comparison & Robustness
- [ ] Cα RMSD calculated between equivalent aligned segments of 7TRE and 7TRD/7TRF.
- [ ] Robustness analysis table documenting which interface contacts persist across cutoff variations vs. which are sensitive to thresholds.
- [ ] Comparison between bound TPP1 (in 7TRE) and unbound OB-fold (2I46) identifying local conformational differences.

### Synthesis & Reporting
- [ ] `results/tables/` populated with CSV outputs for all metrics.
- [ ] Comprehensive `report.md` generated with executive summary, methodology, results, evidence matrix, and biological limitations.
- [ ] Full pipeline reproducible via automated runner script.
</SYSTEM_MESSAGE>


## Follow-up — 2026-10-17T10:11:04Z

The Data Agent Kit plugin needs to be configured.
Do this right away as critical functionality will either be missing or not work correctly if the plugin is not configured.
The following is a <SYSTEM_MESSAGE> not actually sent by the user. It is provided by the system as important information to pay attention to.

<SYSTEM_MESSAGE>
[Message] timestamp=2026-10-17T10:11:04Z sender=78c0bf5a-1c77-4a2a-8652-148476354625 priority=MESSAGE_PRIORITY_HIGH content=Rigorous multi-agent scientific audit, literature prior-art verification, independent recalculation, and falsifiable mechanistic evaluation of human telomerase recruitment (PDB: 7TRE, 7TRD, 7TRF, 7TRC, 2I46) to determine what the structural evidence truly supports regarding the cancer versus healthy tissue maintenance trade-off.

Working directory: C:\Users\hp\.gemini\antigravity\scratch\telomerase-research  
Integrity mode: benchmark  

## Requirements

### R1. Repository Inventory & Evidence Ledger (Phase 0)
Audit existing repository assets, code, tests, and tables. Generate `results/audit/evidence_ledger.csv` and `results/audit/repository_inventory.md` tracing every reported numerical claim (BSA, contact counts, salt bridge distances, RMSDs) to exact inputs, scripts, parameters, and limitations. Classify each claim as established, uncertain, contradicted, or untested.

### R2. Primary Literature & Novelty Gap Audit (Phase 1)
Conduct an exhaustive prior-art audit comparing claims against the original 7TRE publication (Liu et al., Nature 2022), Sekne et al. (Science 2022), and subsequent conformational dynamics studies. Treat recovery of Arg774–Glu168 and Lys78–Glu215 as positive controls, not discoveries. Generate `results/literature/prior_art_matrix.csv`, `results/literature/claim_verification.md`, and `results/literature/novelty_gap_report.md`.

### R3. Falsifiable Hypotheses Formulation (Phase 2)
Define competing hypotheses (H1: conservation/artifact; H2: genuine state-dependent variability; H3: computational sensitivity) regarding the TERT–TPP1 interface. Specify concrete criteria for support and falsification in `results/research/question_and_hypotheses.md`.

### R4. Independent Structural Recalculation & Stress-Testing (Phases 3 & 4)
Using an independent implementation (separate code paths), recalculate Cα RMSDs, buried surface area (BSA), and heavy-atom contacts across distance cutoffs (3.5 Å, 4.0 Å, 4.5 Å) and alternative alignment subsets. Deliver `results/validation/independent_metrics.csv` and `results/interface/sensitivity_analysis.csv`.

### R5. Mechanistic & Allostery Rigor Evaluation (Phases 5 & 6)
- **DE-Loop Remodeling**: Test whether the TPP1 DE-loop displacement represents a genuine state-dependent change vs. construct/crystallographic packing differences. Avoid claiming a sequential kinetic mechanism without dynamic evidence (`results/mechanism/de_loop_mechanism_report.md`).
- **Allosteric Coupling**: Explicitly separate static coordinate proximity (0.338 Å Cα RMSD) from dynamic/energetic coupling. Document why static RMSD alone cannot rule out allosteric effects (`results/mechanism/allostery_evidence_assessment.md`).

### R6. TELIN-1 Provenance Audit & Ligand Reality Check (Phase 8)
Audit `telin1_inhibitor.pdb` and its docked complex. Establish provenance, stereochemistry, and target hypothesis. Strictly label it as an unvalidated hypothetical proposal with zero demonstrated binding affinity, cellular uptake, or cancer selectivity (`results/ligand/TELIN1_evidence_audit.md`).

### R7. Cancer–Aging Evidence Matrix & Scientific Synthesis (Phases 9 & 10)
- Construct `results/translation/cancer_aging_evidence_matrix.csv` and `results/translation/therapeutic_window_limits.md` separating biological facts from clinical speculation.
- Deliver `results/validation_experiments/falsifiable_predictions.md` defining wet-lab validation experiments for future research.
- Undergo independent adversarial review (`results/final_adversarial_review.md`).
- Completely rewrite `report.md` adhering to the required 13-section structure with an explicit list of rejected/overstated claims.

## Acceptance Criteria

### Audit & Evidence Provenance
- [ ] `results/audit/evidence_ledger.csv` created mapping every headline metric to exact code, parameters, and limitations.
- [ ] `results/audit/repository_inventory.md` documents complete Git status, data integrity, and provenance.

### Prior-Art & Novelty
- [ ] `results/literature/prior_art_matrix.csv` maps findings against Liu et al. (Nature 2022) and subsequent literature.
- [ ] `results/literature/novelty_gap_report.md` rigorously classifies what is already established vs. potentially novel.

### Independent Verification & Sensitivity
- [ ] `results/validation/independent_metrics.csv` contains independently recalculated metrics.
- [ ] `results/interface/sensitivity_analysis.csv` records sensitivity to cutoffs and alignment selections.

### Mechanistic De-Hype & Assessment
- [ ] `results/mechanism/de_loop_mechanism_report.md` distinguishes coordinate displacement from sequential binding.
- [ ] `results/mechanism/allostery_evidence_assessment.md` documents why static 0.338 Å RMSD does not prove zero allostery.
- [ ] `results/ligand/TELIN1_evidence_audit.md` explicitly categorizes TELIN-1 as an unvalidated computational candidate.

### Synthesis & Reporting
- [ ] `results/translation/therapeutic_window_limits.md` establishes true requirements for clinical selectivity.
- [ ] `results/validation_experiments/falsifiable_predictions.md` specifies falsifiable wet-lab experiments.
- [ ] `results/final_adversarial_review.md` documents independent challenge.
- [ ] `report.md` rewritten with 13 mandatory sections and a documented list of rejected claims.
</SYSTEM_MESSAGE>
